|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Call JA, Eckhardt SG and Camidge DR:
Targeted manipulation of apoptosis in cancer treatment. Lancet
Oncol. 9:1002–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pitti RM, Marsters SA, Ruppert S, Donahue
CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2
ligand, a new member of the tumor necrosis factor cytokine family.
J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kischkel FC, Lawrence DA, Chuntharapai A,
Schow P, Kim KJ and Ashkenazi A: Apo2L/TRAIL-dependent recruitment
of endogenous FADD and caspase-8 to death receptors 4 and 5.
Immunity. 12:611–620. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Samraj AK, Keil E, Ueffing N,
Schulze-Osthoff K and Schmitz I: Loss of caspase-9 provides genetic
evidence for the type I/II concept of CD95-mediated apoptosis. J
Biol Chem. 281:29652–29659. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herbst RS, Eckhardt SG, Kurzrock R,
Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA,
Tohnya TM, Lum BL, et al: Phase I dose-escalation study of
recombinant human Apo2L/TRAIL, a dual proapoptotic receptor
agonist, in patients with advanced cancer. J Clin Oncol.
28:2839–2846. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soria JC, Smit E, Khayat D, Besse B, Yang
X, Hsu CP, Reese D, Wiezorek J and Blackhall F: Phase 1b study of
dulanermin (recombinant human Apo2L/TRAIL) in combination with
paclitaxel, carboplatin, and bevacizumab in patients with advanced
non-squamous non-small-cell lung cancer. J Clin Oncol.
28:1527–1533. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wiezorek J, Holland P and Graves J: Death
receptor agonists as a targeted therapy for cancer. Clin Cancer
Res. 16:1701–1708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dimberg LY, Anderson CK, Camidge R,
Behbakht K, Thorburn A and Ford HL: On the TRAIL to successful
cancer therapy? Predicting and counteracting resistance against
TRAIL-based therapeutics. Oncogene. 32:1341–1350. 2013. View Article : Google Scholar
|
|
10
|
Prasad S, Kim JH, Gupta SC and Aggarwal
BB: Targeting death receptors for TRAIL by agents designed by
Mother Nature. Trends Pharmacol Sci. 35:520–536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Horak P, Pils D, Haller G, Pribill I,
Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C and
Krainer M: Contribution of epigenetic silencing of tumor necrosis
factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL
resistance and ovarian cancer. Mol Cancer Res. 3:335–343. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bin L, Thorburn J, Thomas LR, Clark PE,
Humphreys R and Thorburn A: Tumor-derived mutations in the TRAIL
receptor DR5 inhibit TRAIL signaling through the DR4 receptor by
competing for ligand binding. J Biol Chem. 282:28189–28194. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Y and Zhang B: TRAIL resistance of
breast cancer cells is associated with constitutive endocytosis of
death receptors 4 and 5. Mol Cancer Res. 6:1861–1871. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grotzer MA, Eggert A, Zuzak TJ, Janss AJ,
Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur GM and Phillips PC:
Resistance to TRAIL-induced apoptosis in primitive neuroectodermal
brain tumor cells correlates with a loss of caspase-8 expression.
Oncogene. 19:4604–4610. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ricci MS, Kim SH, Ogi K, Plastaras JP,
Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, et al:
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib
sensitizes resistant human cancer cells to TRAIL-induced death.
Cancer Cell. 12:66–80. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Munshi A, Pappas G, Honda T, McDonnell TJ,
Younes A, Li Y and Meyn RE: TRAIL (APO-2L) induces apoptosis in
human prostate cancer cells that is inhibitable by Bcl-2. Oncogene.
20:3757–3765. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Finlay D, Vamos M, González-López M,
Ardecky RJ, Ganji SR, Yuan H, Su Y, Cooley TR, Hauser CT, Welsh K,
et al: Small-molecule IAP antagonists sensitize cancer cells to
TRAIL-induced apoptosis: Roles of XIAP and cIAPs. Mol Cancer Ther.
13:5–15. 2014. View Article : Google Scholar :
|
|
18
|
Kocab AJ, Veloso A, Paulsen MT, Ljungman M
and Duckett CS: Effects of physiological and synthetic IAP
antagonism on c-IAP-dependent signaling. Oncogene. 34:5472–5481.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mucha SR, Rizzani A, Gerbes AL, Camaj P,
Thasler WE, Bruns CJ, Eichhorst ST, Gallmeier E, Kolligs FT, Göke
B, et al: JNK inhibition sensitises hepatocellular carcinoma cells
but not normal hepatocytes to the TNF-related apoptosis-inducing
ligand. Gut. 58:688–698. 2009. View Article : Google Scholar
|
|
20
|
Lee HH, Jeong JW, Lee JH, Kim GY, Cheong
J, Jeong YK, Yoo YH and Choi YH: Cordycepin increases sensitivity
of Hep3B human hepatocellular carcinoma cells to TRAIL-mediated
apoptosis by inactivating the JNK signaling pathway. Oncol Rep.
30:1257–1264. 2013.PubMed/NCBI
|
|
21
|
Liu J, Qu X, Xu L, Zhang Y, Qu J, Hou K
and Liu Y: Phosphoinositide 3-kinase/Akt and nuclear factor κB
pathways are involved in tumor necrosis factor-related
apoptosis-inducing ligand resistance in human gastric cancer cells.
Mol Med Rep. 3:491–496. 2010. View Article : Google Scholar
|
|
22
|
Wan Z, Pan H, Liu S, Zhu J, Qi W, Fu K,
Zhao T and Liang J: Downregulation of SNAIL sensitizes
hepatocellular carcinoma cells to TRAIL-induced apoptosis by
regulating the NF-κB pathway. Oncol Rep. 33:1560–1566.
2015.PubMed/NCBI
|
|
23
|
Nazim UM, Jeong JK, Seol JW, Hur J, Eo SK,
Lee JH and Park SY: Inhibition of the autophagy flux by gingerol
enhances TRAIL-induced tumor cell death. Oncol Rep. 33:2331–2336.
2015.PubMed/NCBI
|
|
24
|
Liu YJ, Lin YC, Lee JC, Kuo SC, Ho CT,
Huang LJ, Kuo DH and Way TD: CCT327 enhances TRAIL-induced
apoptosis through the induction of death receptors and
downregulation of cell survival proteins in TRAIL-resistant human
leukemia cells. Oncol Rep. 32:1257–1264. 2014.PubMed/NCBI
|
|
25
|
Pasquier E, Carré M, Pourroy B, Camoin L,
Rebaï O, Briand C and Braguer D: Antiangiogenic activity of
paclitaxel is associated with its cytostatic effect, mediated by
the initiation but not completion of a mitochondrial apoptotic
signaling pathway. Mol Cancer Ther. 3:1301–1310. 2004.PubMed/NCBI
|
|
26
|
Gong J, Yang D, Kohanim S, Humphreys R,
Broemeling L and Kurzrock R: Novel in vivo imaging shows
up-regulation of death receptors by paclitaxel and correlates with
enhanced antitumor effects of receptor agonist antibodies. Mol
Cancer Ther. 5:2991–3000. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hunter TB, Manimala NJ, Luddy KA, Catlin T
and Antonia SJ: Paclitaxel and TRAIL synergize to kill
paclitaxel-resistant small cell lung cancer cells through a
caspase-independent mechanism mediated through AIF. Anticancer Res.
31:3193–3204. 2011.PubMed/NCBI
|
|
28
|
Nimmanapalli R, Perkins CL, Orlando M,
O'Bryan E, Nguyen D and Bhalla KN: Pretreatment with paclitaxel
enhances apo-2 ligand/tumor necrosis factor-related
apoptosis-inducing ligand-induced apoptosis of prostate cancer
cells by inducing death receptors 4 and 5 protein levels. Cancer
Res. 61:759–763. 2001.PubMed/NCBI
|
|
29
|
Lee MJ, Ye AS, Gardino AK, Heijink AM,
Sorger PK, MacBeath G and Yaffe MB: Sequential application of
anticancer drugs enhances cell death by rewiring apoptotic
signaling networks. Cell. 149:780–794. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsuburaya A, Yoshida K, Kobayashi M,
Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura
H, Tatsumoto N, et al: Sequential paclitaxel followed by tegafur
and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant
chemotherapy for T4a/b gastric cancer (SAMIT): A phase 3 factorial
randomised controlled trial. Lancet Oncol. 15:886–893. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Trivedi R, Maurya R and Mishra DP:
Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells
to TRAIL-induced apoptosis through the induction of DR5 and
activation of the ROS-JNK-CHOP pathway. Cell Death Dis.
5:e14652014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McDaid HM and Horwitz SB: Selective
potentiation of paclitaxel (taxol)-induced cell death by
mitogen-activated protein kinase kinase inhibition in human cancer
cell lines. Mol Pharmacol. 60:290–301. 2001.PubMed/NCBI
|
|
33
|
von Haefen C, Wieder T, Essmann F,
Schulze-Osthoff K, Dörken B and Daniel PT: Paclitaxel-induced
apoptosis in BJAB cells proceeds via a death receptor-independent,
caspases-3/-8-driven mitochondrial amplification loop. Oncogene.
22:2236–2247. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Do MT, Na M, Kim HG, Khanal T, Choi JH,
Jin SW, Oh SH, Hwang IH, Chung YC, Kim HS, et al: Ilimaquinone
induces death receptor expression and sensitizes human colon cancer
cells to TRAIL-induced apoptosis through activation of ROS-ERK/p38
MAPK-CHOP signaling pathways. Food Chem Toxicol. 71:51–59. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Paterson AL, Shannon NB, Lao-Sirieix P,
Ong CA, Peters CJ, O'Donovan M and Fitzgerald RC: A systematic
approach to therapeutic target selection in oesophago-gastric
cancer. Gut. 62:1415–1424. 2013. View Article : Google Scholar
|
|
36
|
Söderström TS, Poukkula M, Holmström TH,
Heiskanen KM and Eriksson JE: Mitogen-activated protein
kinase/extracellular signal-regulated kinase signaling in activated
T cells abrogates TRAIL-induced apoptosis upstream of the
mitochondrial amplification loop and caspase-8. J Immunol.
169:2851–2860. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mandal R, Raab M, Matthess Y, Becker S,
Knecht R and Strebhardt K: pERK 1/2 inhibit caspase-8 induced
apoptosis in cancer cells by phosphorylating it in a cell cycle
specific manner. Mol Oncol. 8:232–249. 2014. View Article : Google Scholar
|
|
38
|
Yerbes R, López-Rivas A, Reginato MJ and
Palacios C: Control of FLIP(L) expression and TRAIL resistance by
the extracellular signal-regulated kinase1/2 pathway in breast
epithelial cells. Cell Death Differ. 19:1908–1916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim EY, Ryu JH and Kim AK: CAPE promotes
TRAIL-induced apoptosis through the upregulation of TRAIL receptors
via activation of p38 and suppression of JNK in SK-Hep1
hepatocellular carcinoma cells. Int J Oncol. 43:1291–1300.
2013.PubMed/NCBI
|
